AC1 Inhibition Using ST034307

AC1 was inhibited using the AC1 selective inhibitor ST034307 (Tocris, United Kingdom), which has been shown to demonstrate selectivity for AC1 over other AC isoforms at concentrations below 30 μM (Brust et al., 2017 (link)). In all experiments, ST034307 was dissolved in DMSO to make 3 mM stock prior to addition to experimental solutions at a final concentration of 1 µM and applied for at least 5 min for isolated cells, or 30 min for whole-tissue experiments in order to ensure sufficient tissue penetration.

Free full text: Click here

Bose S.J., Read M.J., Akerman E., Capel R.A., Ayagama T., Russell A., Terrar D.A., Zaccolo M, & Burton R.A. (2022). Inhibition of adenylyl cyclase 1 by ST034307 inhibits IP3-evoked changes in sino-atrial node beat rate. Frontiers in Pharmacology, 13, 951897.

Publication 2022

ST034307

Cells Dmso Isoforms Selectivity Tissue

Top 5 similar protocols

Variable analysis

independent variables

Inhibition of AC1 using the AC1 selective inhibitor ST034307

dependent variables

Unspecified

control variables

Concentration of ST034307 used (1 µM)
Duration of ST034307 application (at least 5 min for isolated cells, or 30 min for whole-tissue experiments)

controls

Positive control: None mentioned
Negative control: None mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!